# | Title | Journal | Year | Citations |
---|
1 | Vaccine hesitancy | Human Vaccines and Immunotherapeutics | 2013 | 1,419 |
2 | Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases | Human Vaccines and Immunotherapeutics | 2020 | 722 |
3 | The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay | Human Vaccines and Immunotherapeutics | 2020 | 582 |
4 | COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey | Human Vaccines and Immunotherapeutics | 2021 | 517 |
5 | COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics | Human Vaccines and Immunotherapeutics | 2020 | 444 |
6 | Measuring trust in vaccination: A systematic review | Human Vaccines and Immunotherapeutics | 2018 | 434 |
7 | The success of microneedle-mediated vaccine delivery into skin | Human Vaccines and Immunotherapeutics | 2016 | 370 |
8 | The rationale for quadrivalent influenza vaccines | Human Vaccines and Immunotherapeutics | 2012 | 325 |
9 | PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations | Human Vaccines and Immunotherapeutics | 2019 | 297 |
10 | Advances in aluminum hydroxide-based adjuvant research and its mechanism | Human Vaccines and Immunotherapeutics | 2015 | 293 |
11 | Talimogene laherparepvec: First in class oncolytic virotherapy | Human Vaccines and Immunotherapeutics | 2018 | 247 |
12 | Mechanisms and pathways of innate immune activation and regulation in health and cancer | Human Vaccines and Immunotherapeutics | 2014 | 246 |
13 | Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus | Human Vaccines and Immunotherapeutics | 2016 | 243 |
14 | Pembrolizumab (Keytruda) | Human Vaccines and Immunotherapeutics | 2016 | 237 |
15 | RTS,S/AS01 vaccine (Mosquirix™): an overview | Human Vaccines and Immunotherapeutics | 2020 | 232 |
16 | COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety | Human Vaccines and Immunotherapeutics | 2022 | 231 |
17 | Provider communication about HPV vaccination: A systematic review | Human Vaccines and Immunotherapeutics | 2016 | 220 |
18 | Polymeric nanoparticles | Human Vaccines and Immunotherapeutics | 2014 | 219 |
19 | Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine | Human Vaccines and Immunotherapeutics | 2014 | 207 |
20 | Transforming growth factor-β: A therapeutic target for cancer | Human Vaccines and Immunotherapeutics | 2017 | 206 |
21 | Adjuvanted influenza vaccines | Human Vaccines and Immunotherapeutics | 2018 | 206 |
22 | A review of Dengvaxia®: development to deployment | Human Vaccines and Immunotherapeutics | 2019 | 206 |
23 | Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature | Human Vaccines and Immunotherapeutics | 2018 | 202 |
24 | Epidemiology of vaccine hesitancy in the United States | Human Vaccines and Immunotherapeutics | 2013 | 200 |
25 | DNA vaccine for cancer immunotherapy | Human Vaccines and Immunotherapeutics | 2014 | 198 |
26 | Japanese encephalitis | Human Vaccines and Immunotherapeutics | 2014 | 196 |
27 | Pre-existing immunity against Ad vectors | Human Vaccines and Immunotherapeutics | 2014 | 195 |
28 | Tocilizumab (Actemra) | Human Vaccines and Immunotherapeutics | 2017 | 193 |
29 | Protein carriers of conjugate vaccines: Characteristics, development and clinical trials | Human Vaccines and Immunotherapeutics | 2013 | 185 |
30 | PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity | Human Vaccines and Immunotherapeutics | 2016 | 184 |
31 | Recent progress in adjuvant discovery for peptide-based subunit vaccines | Human Vaccines and Immunotherapeutics | 2014 | 183 |
32 | Story and science | Human Vaccines and Immunotherapeutics | 2013 | 181 |
33 | The rise (and fall?) of parental vaccine hesitancy | Human Vaccines and Immunotherapeutics | 2013 | 179 |
34 | Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? | Human Vaccines and Immunotherapeutics | 2022 | 176 |
35 | Comparison of HDAC inhibitors in clinical development | Human Vaccines and Immunotherapeutics | 2013 | 173 |
36 | Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future | Human Vaccines and Immunotherapeutics | 2013 | 173 |
37 | Phage display—A powerful technique for immunotherapy | Human Vaccines and Immunotherapeutics | 2012 | 171 |
38 | A novel, disruptive vaccination technology | Human Vaccines and Immunotherapeutics | 2013 | 171 |
39 | Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine | Human Vaccines and Immunotherapeutics | 2012 | 168 |
40 | Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity | Human Vaccines and Immunotherapeutics | 2017 | 168 |
41 | HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe | Human Vaccines and Immunotherapeutics | 2019 | 168 |
42 | Assessing COVID-19 vaccine literacy: a preliminary online survey | Human Vaccines and Immunotherapeutics | 2021 | 168 |
43 | A qualitative insight into the perceptions and COVID-19 vaccine hesitancy among Pakistani pharmacists | Human Vaccines and Immunotherapeutics | 2022 | 167 |
44 | Health literacy and vaccination: A systematic review | Human Vaccines and Immunotherapeutics | 2018 | 166 |
45 | Vaccines and routine immunization strategies during the COVID-19 pandemic | Human Vaccines and Immunotherapeutics | 2021 | 165 |
46 | Vaccines against invasiveSalmonelladisease | Human Vaccines and Immunotherapeutics | 2014 | 163 |
47 | Peptide/protein vaccine delivery system based on PLGA particles | Human Vaccines and Immunotherapeutics | 2016 | 163 |
48 | The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review | Human Vaccines and Immunotherapeutics | 2022 | 163 |
49 | From discovery to licensure, the Adjuvant System story | Human Vaccines and Immunotherapeutics | 2017 | 160 |
50 | Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines | Human Vaccines and Immunotherapeutics | 2013 | 157 |